Product
Nivolumab + SOX
1 clinical trial
2 indications
Indication
ImmunosuppressionIndication
Stomach CancerClinical trial
A Multicenter, Prospective, Phase Ⅱ Clinical Study of Nivolumab Combined With SOX in the Perioperative Treatment of Locally Advanced Gastric and Gastroesophageal Junction AdenocarcinomaStatus: Recruiting, Estimated PCD: 2023-12-31